midphase
AltruBio Secures $225M for Midphase Ulcerative Colitis Program Following Checkpoint Drug Modification
AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.
Actionable Insights Powered by AI
AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.